Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Purpose: Even when diagnosed prior to metastasis, pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with almost 90% lethality, emphasizing the need for new therapies optimally targeting the tumors of individual patients. Experimental Design: We first developed a panel of new physiologic models for study of PDAC, expanding surgical PDAC tumor samples in culture using short-term culture and conditional reprogramming with the Rho kinase inhibitor Y-27632, and creating matched patient-derived xenografts (PDX). These were evaluated for sensitivity to a large panel of clinical agents, and promising leads further evaluated mechanistically. Results: Only a small minority of tested agents was cytotoxic in minimally passaged PDAC cultures in vitro. Drugs interfering with protein turnover and transcription were among most cytotoxic. Among transcriptional repressors, triptolide, a covalent inhibitor of ERCC3, was most consistently effective in vitro and in vivo causing prolonged complete regression in multiple PDX models resistant to standard PDAC therapies. Importantly, triptolide showed superior activity in MYC-amplified PDX models and elicited rapid and profound depletion of the oncoprotein MYC, a transcriptional regulator. Expression of ERCC3 and MYC was interdependent in PDACs, and acquired resistance to triptolide depended on elevated ERCC3 and MYC expression. The Cancer Genome Atlas analysis indicates ERCC3 expression predicts poor prognosis, particularly in CDKN2A-null, highly proliferative tumors. Conclusions: This provides initial preclinical evidence for an essential role of MYC–ERCC3 interactions in PDAC, and suggests a new mechanistic approach for disruption of critical survival signaling in MYC-dependent cancers. Clin Cancer Res; 22(24); 6153–63. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“These include gemcitabine [11]; erlotinib [12] and nab-paclitaxel [13] (both used in combination with gemcitabine); and the topoisomerase 1 inhibitor irinotecan, used in combination with fluorouracil and oxaliplatin (FOLFIRINOX [14]), or with fluorouracil and nanoliposomal irinotecan [15]).”
BackgroundLamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 4×
“MYC copy number was quantified relative to ALB based on the relative stability of ALB chromosomal locus 4q11-q13 in PDAC[3].”
BackgroundMethodInfluentialSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 2×
“We used area under the curve (AUC) to assess the drug’s cytotoxicity as described [24].”
MethodPancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 4×
“Genetic loss of CDKN2A, encoding p16, is common in PDAC and associated with deregulation of cell cycle control [2, 3].”
BackgroundInfluentialWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115 · cited 2×
“Importantly, control of tumor growth with these therapies involved limiting activity of MYC, which is a critical promoter of pancreatic carcinogenesis [48], and for which high expression is known to be a poor prognostic factor for PDAC [4].”
BackgroundYeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells
Liu, X., Ory, V., Chapman, S., Yuan, H., Albanese, C., Kallakury, B., Timofeeva, O. A., Nealon, C., Dakic, A., Simic, V., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.036 · Cited by 726
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3342 · Cited by 288 · cited 4×
“Comparisons between the chemosensitivity of rapid cultures of pancreatic carcinoma cells and the NCI-60 cell lines panel were made using the publicly available data from the CellMiner database (http://discover.nci.nih.gov/cellminer).”
MethodInfluential
Cited by
Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens
Liu, X., Krawczyk, E., Suprynowicz, F. A., Palechor-Ceron, N., Yuan, H., Dakic, A., Simic, V., Zheng, Y.-L., Sripadhan, P., Chen, C., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2016.174 · Cited by 299
Li, L., He, D., Guo, Q., Zhang, Z., Ru, D., Wang, L., Gong, K., Liu, F., Duan, Y., & Li, H. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01264-5 · Cited by 206
Precision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 195
Timofeeva, O. A., Palechor-Ceron, N., Li, G., Yuan, H., Krawczyk, E., Zhong, X., Liu, G., Upadhyay, G., Dakic, A., Yu, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13937 · Cited by 65
Conditionally Reprogrammed Cells as Preclinical Model for Rare Cancers
Krawczyk, E. (2025) · Cancers · doi:10.3390/cancers17172834 · Cited by 1
Metadata
- Authors
- Beglyarova, N., Banina, E., Zhou, Y., Mukhamadeeva, R., Andrianov, G., Bobrov, E., Lysenko, E., Skobeleva, N., Gabitova, L., Restifo, D., Pressman, M., Serebriiskii, I. G., Hoffman, J. P., Paz, K., Behrens, D., Khazak, V., Jablonski, S. A., Golemis, E. A., Weiner, L. M., & Astsaturov, I.
- Venue
- Clinical Cancer Research
- Published
- 2016-12-15
- Volume
- 22
- Issue
- 24
- Pages
- 6153-6163
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2466451217
- Cited by
- 61
- References
- 12
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0149
- The paper
- Beglyarova, N., Banina, E., Zhou, Y., Mukhamadeeva, R., Andrianov, G., Bobrov, E., Lysenko, E., Skobeleva, N., Gabitova, L., Restifo, D., Pressman, M., Serebriiskii, I. G., Hoffman, J. P., Paz, K., Behrens, D., Khazak, V., Jablonski, S. A., Golemis, E. A., Weiner, L. M., & Astsaturov, I. (2016). Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0149
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.